Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9, 263

Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy


Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy

Jing Jin et al. Front Oncol.


The introduction of targeted therapy is the biggest success in the treatment of cancer in the past few decades. However, heterogeneous cancer is characterized by diverse molecular alterations as well as multiple clinical profiles. Specific genetic mutations in cancer therapy targets may increase drug sensitivity, or more frequently result in therapeutic resistance. In the past 3 years, several novel targeted therapies have been approved for cancer treatment, including drugs with new targets (i.e., anti-PD1/PDL1 therapies and CDK4/6 inhibitors), mutation targeting drugs (i.e., the EGFR T790M targeting osimertinib), drugs with multiple targets (i.e., the EGFR/HER2 dual inhibitor neratinib) and drug combinations (i.e., encorafenib/binimetinib and dabrafenib/trametinib). In this perspective, we focus on the most up-to-date knowledge of targeted therapy and describe how genetic mutations influence the sensitivity of targeted therapy, highlighting the challenges faced within this era of precision medicine. Moreover, the strategies that deal with mutation-driven resistance are further discussed. Advances in these areas would allow for more targeted and effective therapeutic options for cancer patients.

Keywords: EGFR; PD-1/PD-L1; cyclin-dependent kinases 4/6; resistance; somatic mutation; targeted therapy.

Similar articles

See all similar articles

Cited by 1 article


    1. Scotti L, Mendonca Junior FJ, Ishiki HM, Ribeiro FF, Singla RK, Barbosa Filho JM, et al. . Docking studies for multi-target drugs. Curr Drug Targ. (2017) 18:592–604. 10.2174/1389450116666150825111818 - DOI - PubMed
    1. Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. (2017) 355:1330–4. 10.1126/science.aaf9011 - DOI - PMC - PubMed
    1. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. . Distinct sets of genetic alterations in melanoma. N Engl J Med. (2005) 353:2135–47. 10.1056/NEJMoa050092 - DOI - PubMed
    1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. . Mutations of the BRAF gene in human cancer. Nature. (2002) 417:949–54. 10.1038/nature00766 - DOI - PubMed
    1. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. . Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. (2012) 380:358–65. 10.1016/s0140-6736(12)60868-x - DOI - PubMed